Literature DB >> 34568970

Plasma neurofilament light chain level and orthostatic hypotension in early Parkinson's disease.

Don Gueu Park1, Jae Whan Kim2, Young-Sil An3, Jaerak Chang4,5, Jung Han Yoon6.   

Abstract

To delineate the impact of non-motor markers (REM sleep behavior disorder (RBD), orthostatic hypotension (OH), cardiac sympathetic denervation, hyposmia) on neuronal injury in early-stage Parkinson's disease (PD), we measured the plasma neurofilament light chain (NFL) level of PD patients and evaluated its relationship with these markers. The study population comprised a cohort of 77 patients with PD and 54 controls. OH was assessed using 5-min head-up tilt-table test. Other clinical parameters such as RBD, Unified Parkinson's Disease Rating Scale (UPDRS), cognition, Cross-Cultural Smell Identification Test (CCSIT), white matter hyperintensity (WMH), cardiac metaiodobenzylguanidine (MIBG) and striatal dopamine transporter (DAT) uptake were assessed. Plasma NFL levels were measured using Simoa platform. During mean 24.8 months of follow-up, 70 patients remained PD, 5 patients converted to Parkinson-plus syndrome (P + converter), and 2 were lost to follow-up. NFL level did not differ between PD and control groups (age-adjusted means 10.40 pg/mL vs 9.51 pg/mL, p = 0.151), but PD patients with OH (median 15.31 pg/mL) had higher levels compared with those without OH (median 9.2 pg/mL, p = 0.008), as well as the control group (median 9.7 pg/mL, p = 0.002). P + converter group had the highest plasma NFL level (38.17 pg/mL, p < 0.001). In a multiple regression analysis, OH, age, and disease duration independently correlated with plasma NFL level. This finding adds biomarker-based evidence for poor clinical outcomes associated with OH in patients with PD.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  MIBG; NFL; Orthostatic hypotension; Parkinson’s disease; RBD

Mesh:

Substances:

Year:  2021        PMID: 34568970     DOI: 10.1007/s00702-021-02423-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  24 in total

1.  Survival in synucleinopathies: A prospective cohort study.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi; Tianxia Wu
Journal:  Neurology       Date:  2015-10-02       Impact factor: 9.910

2.  Association of Autonomic Dysfunction With Disease Progression and Survival in Parkinson Disease.

Authors:  Eduardo De Pablo-Fernandez; Carmen Tur; Tamas Revesz; Andrew J Lees; Janice L Holton; Thomas T Warner
Journal:  JAMA Neurol       Date:  2017-08-01       Impact factor: 18.302

3.  Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.

Authors:  Seyed-Mohammad Fereshtehnejad; Yashar Zeighami; Alain Dagher; Ronald B Postuma
Journal:  Brain       Date:  2017-07-01       Impact factor: 13.501

4.  Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease.

Authors:  Eduardo De Pablo-Fernández; Andrew J Lees; Janice L Holton; Thomas T Warner
Journal:  JAMA Neurol       Date:  2019-04-01       Impact factor: 18.302

5.  Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro.

Authors:  Woo Hee Choi; Yoo Hyun Um; Won Sang Jung; Sung Hoon Kim
Journal:  Ann Nucl Med       Date:  2016-08-27       Impact factor: 2.668

6.  Cardiac sympathetic denervation and dementia in de novo Parkinson's disease: A 7-year follow-up study.

Authors:  Mun Hee Choi; Jung Han Yoon; Suk Woo Yong
Journal:  J Neurol Sci       Date:  2017-09-08       Impact factor: 3.181

7.  Development of the 12-item Cross-Cultural Smell Identification Test (CC-SIT).

Authors:  R L Doty; A Marcus; W W Lee
Journal:  Laryngoscope       Date:  1996-03       Impact factor: 3.325

8.  Effects of orthostatic hypotension on cognition in Parkinson disease.

Authors:  Justin Centi; Roy Freeman; Christopher H Gibbons; Sandy Neargarder; Alexander O Canova; Alice Cronin-Golomb
Journal:  Neurology       Date:  2016-11-30       Impact factor: 9.910

9.  White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson's Disease.

Authors:  Mahsa Dadar; Seyed-Mohammad Fereshtehnejad; Yashar Zeighami; Alain Dagher; Ronald B Postuma; D Louis Collins
Journal:  Mov Disord Clin Pract       Date:  2020-07-18

10.  NfL as a biomarker for neurodegeneration and survival in Parkinson disease.

Authors:  David Bäckström; Jan Linder; Susanna Jakobson Mo; Katrine Riklund; Henrik Zetterberg; Kaj Blennow; Lars Forsgren; Niklas Lenfeldt
Journal:  Neurology       Date:  2020-07-17       Impact factor: 11.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.